It was anticipated & expected for the pullback to occur, I'm certain many sold on highs to only buy back at the discount price. The anticipation of a sudden recovery initiated by another announcement is probable. Quite frankly, shorters' create nice buying opportunities for those that are patient without the financial pressures to settle trades or constrained through margin lending. The Mesoblast story has hit the media channels quite well and gained momentum that will keep building. The due diligence applied is testament to Mesoblast professional approach to not just one but several initiatives being developed for commercial application.
Ann: FDA Grants RMAT Designation for Rexlemestrocel-L in CLBP, page-125
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
-0.020(1.78%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.12 | $1.13 | $1.09 | $4.556M | 4.141M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 9590 | $1.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.11 | 3132 | 1 |
View Market Depth
| Last trade - 16.10pm 18/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |